Orthopedics – OsteoArthritis (OA)
Cesca is in early stage development of an autologous stem cell-based therapy intended to treat patients with cartilage tissue degeneration that may lead to progressive cartilage loss and painful joint diseases. Localized articular cartilage defects can potentially be repaired by transplantation of autologous cell therapy. Therapies in development using Cesca’s proprietary MXP™ system are expected to delay further deterioration and repair the damaged joint cartilage. Treatment is typically via one single procedure in the hospital or clinic.
TotipotentRX Cellular Medicine Inc (BVI).
185 Technology Dr Suite 150, Irvine California 92618
Tel : 1 (888) 379-2670